Selective Serotonin Reuptake Inhibitors (SSRIs), the most widely used depression drug, influences bone formation and increases bone fracture risks, a new study finds.
A new study says that Selective Serotonin Reuptake Inhibitors (SSRIs), the most widely used depression drug, reduce bone formation and increase bone fracture risks. Bone metabolism is affected by osseointegration and the researchers have delved into the association between SSRIs and the risk of failures in osseointegrated dental implants
The study was conducted on 490 patients treated with dental implants from January 2007 to January 2013. A total of 916 implants were reported, which were used to estimate the risk of failure associated with the use of SSRIs. Researchers also used data related to cox proportional hazards, generalized estimating equations models and Kaplan-Meier for their study. A follow-up was conducted for 6 years and seven months. At the end of the study, 38 dental implants failed and 784 succeeded in non-users group while 10 failed and 84 succeeded in SSRIs-users group. The study revealed failure rate of 4.6 percent in people who weren't on SSRIs and 10.6 percent in those who were on SSRIs.
Researchers also noted that small implant diameters, bone augmentation and smoking habits also increased the risk of implant failure.
Last year, a team of researchers also found that people who take antidepressants are at a higher risk of type 2 diabetes. Previous studies have linked several antidepressants with significant weight gain, which increases the risk of type 2 diabetes. However, several studies which explored this association also observed an increased risk of diabetes after adjustment for changes in body weight, implying other factors could be involved.
Findings were published in the OnlineFirst portion of the IADR/AADR Journal of Dental Research (JDR).
